Transthyretin-related vitreous amyloidosis in different endemic areas
- 1 September 2010
- journal article
- research article
- Published by Taylor & Francis in Amyloid
- Vol. 17 (3-4) , 105-108
Abstract
Background. To investigate the vitreous opacity in patients with familial amyloidotic polyneuropathy (FAP) in two major endemic areas, Japan and Sweden. Methods. We obtained clinical data for 90 patients with vitreous opacity that was associated with FAP amyloidogenic transthyretin (ATTR) Val30Met; 18 Japanese patients and 72 Swedish patients. We reviewed medical records at Kumamoto University Hospital in Japan and Umeå University Hospital in Sweden. We evaluated the characteristics of the patients, systemic and ocular histories, clinical findings and treatment. Results. Swedish patients were significantly older at the onset of vitreous opacity (mean age 67.8 years) than were Japanese patients (47.6 years). A similar age difference was found for the onset of polyneuropathy. In addition, Swedish patients without polyneuropathy were significantly older (74.1 years) at the onset of vitreous opacity than those with polyneuropathy (64.6 years). A significant difference in the occurrence of vitreous opacity as the only manifestation of FAP was seen for Swedish patients (35%) compared with Japanese patients (6%). Conclusions. Swedish FAP ATTR Val30Met patients appeared to develop vitreous opacity later and more frequently compared with Japanese patients.Keywords
This publication has 12 references indexed in Scilit:
- Transthyretin-Related Familial Amyloidotic PolyneuropathyArchives of Neurology, 2005
- Impact of homozygosity for an amyloidogenic transthyretin mutation on phenotype and long term outcomeJournal of Medical Genetics, 2005
- A case of vitreous amyloidosis without systemic symptoms in familial amyloidotic polyneuropathyAmyloid, 2004
- Trans -Suppression of Misfolding in an Amyloid DiseaseScience, 2001
- Review: Modulating Factors in Amyloid-β Fibril FormationJournal of Structural Biology, 2000
- Compound heterozygotes of transthyretin Met30 and transthyretin Met119 are protected from the devastating effects of familial amyloid polyneuropathyNeuromuscular Disorders, 1996
- Ocular amyloidosis, with special reference to thehereditary forms with vitreous involvementSurvey of Ophthalmology, 1995
- Familial Amyloidotic Polyneuropathy in Sweden: Geographical Distribution, Age of Onset, and PrevalenceHuman Heredity, 1993
- Proteoglycans in the pathogenesis of Alzheimer's disease and other amyloidosesNeurobiology of Aging, 1989
- Type I familial amyloidotic polyneuropathy (Japanese type)Brain and Development, 1984